Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings

Alnylam Pharmaceuticals Inc., a leading RNAi therapeutics company, and the University of Massachusetts Medical School reported today that the European Patent Office has upheld the Tuschl I '726 patent in oral opposition proceedings held in Munich, Germany. The requested claims of the '726 patent were upheld without any modification. Opponents included Sanofi-Aventis Deutschland GmbH, Silence Therapeutics AG, and BASF SE. Read more